ClinicalTrials.gg
Not yet recruitingNCT07641166Updated Jun 11, 2026

Manual Diaphragmatic Release on Exercise Capacity and Quality of Life in Women With Fibromyalgia

An interventional study of Manual Diaphragmatic Release and Aerobic Training in Fibromyalgia, sponsored by Middle East University. Not yet recruiting. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Middle East University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

Evaluate the effect of manual diaphragmatic release on exercise capacity, inspiratory muscles strength, symptoms severity, and health-related quality of life in women diagnosed with fibromyalgia.

Read the detailed description

Sixty women diagnosed with fibromyalgia will be recruited from outpatient rheumatology and physical therapy clinics. Following clinical screening, patients will be randomly assigned into two parallel groups:

The Study Group: Will include 30 women participating in manual diaphragmatic release plus aerobic training for 8 weeks.

The Control Group: Will include 30 women participating in aerobic training only for 8 weeks.

At baseline and post-study (after 8 weeks), outcomes will be comprehensively assessed. The primary focus is to determine whether manual release of the diaphragm improves exercise capacity, minimizes the overall impact of fibromyalgia symptoms, improves health-related quality of life metrics, and enhances respiratory muscles strength.

02

Conditions studied

  • Fibromyalgia

Browse trials for

03

In context

Fibromyalgia

1,243 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 937 interventional studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

Middle East University is the lead sponsor of 19 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed clinical diagnosis of fibromyalgia fulfilling the American College of Rheumatology diagnostic criteria.
  • Sedentary or low physical activity status (not participating in structured exercise programs within the past 3 months).

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric comorbidities (e.g., major depressive disorder with active suicidal ideation) or cognitive impairments.
  • Presence of comorbid rheumatologic or conditions that overlap with muscle/joint symptoms (e.g., severe rheumatoid arthritis, systemic lupus erythematosus).
  • Primary chronic respiratory/chest diseases (e.g., severe or active asthma).
  • Cardiovascular disorders or uncontrolled hypertension.
  • Pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Study group

    30 women with fibromyalgia who will receive manual diaphragmatic release sessions followed by a structured aerobic training program on a cycle ergometer for 8 weeks

    Other: Manual Diaphragmatic Release · Other: Aerobic Training

  • Active comparator
    Control group

    30 women with fibromyalgia who will participate in the standardized aerobic training program alone for 8 weeks.

    Other: Aerobic Training

Interventions

  • OtherManual Diaphragmatic Release

    Thrice a week for 8 weeks, the participant will assume a supine position with relaxed limbs. The therapist will position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. During the inspiratory phase, the therapist gently pulls the contact points toward the head and slightly laterally, progressively deepening contact within the costal margin over successive respiratory cycles to release restriction.

  • OtherAerobic Training

    3 sessions per week consisting of 30-45 minutes of cycling at low-to-moderate intensity on a cycle ergometer. Intensity will be managed at a workout heart rate ranging between 60% to 70% of the maximal heart rate, accompanied by a brief warm-up and cool-down phase.

06

What researchers measure

Primary outcomes

  1. Exercise Capacity

    Maximal Oxygen Consumption via Cardiopulmonary Exercise Testing

    Time frame: Baseline and after 8 weeks

Secondary outcomes

  1. Health-Related Quality of Life

    Health-related quality of life will be assessed using the 12-Item Short Form Health Survey. The survey provides scores for physical and mental health status, with scores ranging from 0 to 100, where higher scores indicate better health-related quality of life.

    Time frame: Baseline and after 8 weeks

  2. Fibromyalgia Symptom Severity

    Symptoms will be assessed using the Revised Fibromyalgia Impact Questionnaire. The total score ranges from 0 to 100, with higher scores indicating greater symptom severity and a greater impact of fibromyalgia on daily functioning and quality of life.

    Time frame: Baseline and after 8 weeks

  3. Respiratory Muscle Strength

    Maximal Inspiratory Pressure and Maximal Expiratory Pressure will be tested

    Time frame: Baseline and after 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07641166
Lead sponsor
Middle East University
Responsible party
Saher Lotfy El Gayar (Assistant Professor of Physical Therapy, Middle East University) — Principal investigator
First posted
Jun 11, 2026
Start date
Jun 17, 2026 (estimated)
Primary completion
Nov 3, 2026 (estimated)
Completion
Nov 8, 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

Saher Lotfy Elgayar, Ph.D
Contact
saherlotfy020@gmail.com
+201020429911
Mohammed Youssef Elhamrawy, Ph.D
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion